An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus

por Eisenberg, RA, Khan, S, Stansberry, J, Tsai, D, Kolasinski, S, Rieder, E, Kotzin, B, Looney, RJ, Strieber, C, Albert, D
Publicado 2004